...

首页> 外文期刊>Headache >Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications

【24h】

Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications

机译：偏头痛患者的弗里曼扎姆布的多中心，随机，安慰剂对焦研究的安全性和耐受性结果，并记录了对2-4级偏头痛预防药物的反应不足

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2019年第1期|共2页
作者
Ferrari M. D.; Cohen J. M.; Ning X.; Galic M.; Yang R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献

1. Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications [J] . Ferrari M. D., Cohen J. M., Ning X., Headache . 2019,第Suppla1期

机译：偏头痛患者的弗里曼扎姆布的多中心，随机，安慰剂对焦研究的安全性和耐受性结果，并记录了对2-4级偏头痛预防药物的反应不足
2. Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Multicenter, Randomized, Placebo-controlled FOCUS Study [J] . Spierings E., Ning X., Galic M., Headache . 2019,第Suppla1期

机译：对偏头痛患者进行临床有意义的反应，并记录了在多中心，随机，安慰剂控制的重点研究中对2-4级偏头痛预防药物的反应不足
3. Improvement in Headache-related Disability with Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the International, Multicenter, Randomized FOCUS Study [J] . Ashina M., Ferrari M. D., Ning X., Headache . 2019,第Suppla1期

机译：用偏头痛患者的Fremanezumab改善与Fremanezumab有关的残疾，并记录了在国际，多中心，随机焦点研究中对2-4次偏头痛预防药物课程的不足反应
4. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized placebo-controlled trial [O] . Egilius L. H. Spierings, Mikko Kärppä, Xiaoping Ning, 2021

机译：Fremanezumab在偏头痛患者中的疗效和安全性和对前预防治疗的反应不足：亚组通过随机安慰剂对照试验的国家分析
5. Efficacy of fremanezumab by country in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled focus study [O] . E.L.H. Spierings, X. Ning, J.M. Cohen, 2019

机译：在多期一组，随机安慰剂控制的重点研究中对患者患者患者进行了患者患者患者的疗效患者的疗效，随机安慰剂对焦点研究中的2-4级偏头痛预防药物

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号